Streetwise Reports' Article Archives — March 2019 back to current month (29)
The company will discuss the trial when it hosts a conference call about this specific disease indication in April.
With this development, the Canadian company further expands its U.S. footprint.
The "encouraging" data for this drug candidate as a monotherapy is the focus of an H.C. Wainwright & Co. report.
Peter Epstein of Epstein Research profiles a gold company that plans to grow hemp seed on its land.
This clinical decision support software integration is the first of its kind, according to the company.
An H.C. Wainwright & Co. report discussed what sets this company's asset apart from similar products.
This U.S. study follows encouraging results from a Phase 1b trial in the same indication in Australia.
The company cites the recent discontinuation of other firms' clinical programs as proof.
A ROTH Capital Partners report reviewed this New Jersey firm's plans for its lead asset.
An H.C. Wainwright & Co. report discussed what those are and why they could impact the biotech's valuation.
Rare Diseases Biotech Provides Opportunity (03/21/2019)
A ROTH Capital Partners report discussed why the stock price is at its current level and noted upcoming catalysts for the company.
The company will roll out virtual, remote medical services to change how primary care practices are run.
The likely timelines for approval and commercialization of each drug are discussed in an H.C. Wainwright report.
This Canadian company intends to next launch a marketing campaign for the new product suite.
Steve Palmer, Founding Partner, President and Chief Investment Officer for AlphaNorth Asset Management, talks about a handful of companies in diverse industries that have his attention.
The biotech was selected to discuss its antibodies that selectively target toxic forms of alpha-synuclein.
A Ladenburg Thalmann report reviewed the study design and purpose.
Technical analyst Clive Maund discusses both the fundamentals and technicals for this company that just signed a cannabis distribution agreement with a Vancouver-based retailer.
This company forges partnerships with cannabis companies to deliver, within an hour, their products to customers.
The new platform promises to provide a unique e-commerce experience in the legal cannabis industry, combining customer education and support for online transactions.
Marijuana: Up in Smoke (03/13/2019)
Sector expert Ron Struthers takes a look at a spectrum of cannabis companies, including one company that's gone from a high to a downer, a sector leader, and a firm that promotes CBDs as good for sex.
This California company expects results from clinical trials in liver disease and psoriasis in 2019.
Proprietary OxC-beta livestock feed supplement can supplant the need for maintenance antibiotics.
Coverage Initiated on Cancer Vaccine Firm (03/09/2019)
An H.C. Wainwright & Co. report explained the reasons for its "bullish view" on this California-based life sciences company.
A ROTH Capital Partners report presented the reasons for investing in this company.
The companies aim to combine their expertise to co-create immersive and compelling instructive medical tools.
By tucking in this retinal gene therapy firm, the Massachusetts-based company gains assets and synergy.
This new initiative combines emerging technologies and human skill-based expertise.
An H.C. Wainwright & Co. report explained the purpose of the funding and how any resulting developments would positively impact the former parent company.
|"DRRX's psoriasis trial is on target for topline data by year-end 2019."|